Literature DB >> 9564194

The problem of measurement error in multisite clinical trials.

M A Demitrack1, D Faries, J M Herrera, D DeBrota, W Z Potter.   

Abstract

The implementation of a multisite, randomized, clinical psychopharmacologic trial involves a substantial investment of time and effort on the part of all participants. Because of their complexity, such clinical trials present unique methodological and design challenges. Indeed, it is not uncommon for such studies to conclude with uninterpretable results, due in part to such methodological pitfalls. It has been suggested that clarification of such methodologic dilemmas is one of the most important challenges facing the future of industry-sponsored psychopharmacologic drug development. Among the many factors that may contribute to problematic clinical trial results, error in measuring the phenomena being studied is of particular concern. In this article, we describe the outcome of an intensive series of interrater reliability training sessions for the 17-item Hamilton Depression Rating Scale conducted at the start of a Phase II multisite clinical drug trial. The data underscore the magnitude of error present in such a test setting and provide preliminary evidence for the potential effect of this problem on the detection of clinical change.

Entities:  

Mesh:

Year:  1998        PMID: 9564194

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  21 in total

Review 1.  Alzheimer's disease drug development in 2008 and beyond: problems and opportunities.

Authors:  Robert E Becker; Nigel H Greig
Journal:  Curr Alzheimer Res       Date:  2008-08       Impact factor: 3.498

2.  Has the rising placebo response impacted antidepressant clinical trial outcome? Data from the US Food and Drug Administration 1987-2013.

Authors:  Arif Khan; Kaysee Fahl Mar; Jim Faucett; Shirin Khan Schilling; Walter A Brown
Journal:  World Psychiatry       Date:  2017-06       Impact factor: 49.548

3.  Does differential drop-out explain the influence of study design on antidepressant response? A meta-analysis.

Authors:  Bret R Rutherford; Joel R Sneed; Steven P Roose
Journal:  J Affect Disord       Date:  2012-03-02       Impact factor: 4.839

4.  Increasing the success rate for Alzheimer's disease drug discovery and development.

Authors:  Robert E Becker; Nigel H Greig
Journal:  Expert Opin Drug Discov       Date:  2012-03-23       Impact factor: 6.098

Review 5.  Design and conduct of confirmatory chronic pain clinical trials.

Authors:  Nathaniel Katz
Journal:  Pain Rep       Date:  2020-12-18

6.  Voice acoustic measures of depression severity and treatment response collected via interactive voice response (IVR) technology.

Authors:  James C Mundt; Peter J Snyder; Michael S Cannizzaro; Kara Chappie; Dayna S Geralts
Journal:  J Neurolinguistics       Date:  2007-01       Impact factor: 1.710

7.  Fire in the ashes: can failed Alzheimer's disease drugs succeed with second chances?

Authors:  Robert E Becker; Nigel H Greig
Journal:  Alzheimers Dement       Date:  2012-03-30       Impact factor: 21.566

Review 8.  Why so few drugs for Alzheimer's disease? Are methods failing drugs?

Authors:  R E Becker; N H Greig
Journal:  Curr Alzheimer Res       Date:  2010-11       Impact factor: 3.498

Review 9.  Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?

Authors:  Robert E Becker; Nigel H Greig; Ezio Giacobini
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

10.  Neuropsychiatric clinical trials: should they accommodate real-world practices or set standards for clinical practices?

Authors:  Robert E Becker; Nigel H Greig
Journal:  J Clin Psychopharmacol       Date:  2009-02       Impact factor: 3.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.